[
  {
    "ts": null,
    "headline": "Pfizer Declares First-Quarter 2026 Dividend",
    "summary": "NEW YORK, December 12, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.",
    "url": "https://finnhub.io/api/news?id=9b813e0d74f18852970affd5127ba56c44334f042cc82abd89e4b683f969f5ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765558800,
      "headline": "Pfizer Declares First-Quarter 2026 Dividend",
      "id": 137769495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 12, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.",
      "url": "https://finnhub.io/api/news?id=9b813e0d74f18852970affd5127ba56c44334f042cc82abd89e4b683f969f5ae"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.",
    "summary": "Keep your expectations in check.",
    "url": "https://finnhub.io/api/news?id=cbdd99236c9fb9a228d2370ea82e2ba07c69f4aeeedb5388833d06bcd204f34b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765558320,
      "headline": "Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.",
      "id": 137769496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Keep your expectations in check.",
      "url": "https://finnhub.io/api/news?id=cbdd99236c9fb9a228d2370ea82e2ba07c69f4aeeedb5388833d06bcd204f34b"
    }
  },
  {
    "ts": null,
    "headline": "GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)",
    "summary": "Discover why GSK is upgraded to 'Strong Buy' with strong earnings, new drug approvals, and low P/E valuation.",
    "url": "https://finnhub.io/api/news?id=47d4986b94f4f823645b03528c249884f1a5e3488d42f6f9b6b96af8685a05fe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765557767,
      "headline": "GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)",
      "id": 137771795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/939034648/image_939034648.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why GSK is upgraded to 'Strong Buy' with strong earnings, new drug approvals, and low P/E valuation.",
      "url": "https://finnhub.io/api/news?id=47d4986b94f4f823645b03528c249884f1a5e3488d42f6f9b6b96af8685a05fe"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win",
    "summary": "LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.",
    "url": "https://finnhub.io/api/news?id=b219fac2558d26ecf380e490b1e8acf0097923ed1b21f46ba1b32ba9821b63a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765556220,
      "headline": "Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win",
      "id": 137769272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.",
      "url": "https://finnhub.io/api/news?id=b219fac2558d26ecf380e490b1e8acf0097923ed1b21f46ba1b32ba9821b63a9"
    }
  },
  {
    "ts": null,
    "headline": "The Best Turnaround Stock to Invest $1,000 in Right Now",
    "summary": "Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.",
    "url": "https://finnhub.io/api/news?id=1b76b1faadd3a83833ecc198afa9566f376e40ff8ac2930ead2908e58620301d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553700,
      "headline": "The Best Turnaround Stock to Invest $1,000 in Right Now",
      "id": 137769498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.",
      "url": "https://finnhub.io/api/news?id=1b76b1faadd3a83833ecc198afa9566f376e40ff8ac2930ead2908e58620301d"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends",
    "summary": "Get the latest on the Dividend Harvesting Portfolio: 32.6% returns, 8% yield, and strategies to optimize income amid market shifts.",
    "url": "https://finnhub.io/api/news?id=62143e9809113f40aaa2c2b687060be2bbc505ad8cfd357aa8c46711ad5182f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765529100,
      "headline": "Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends",
      "id": 137767587,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Get the latest on the Dividend Harvesting Portfolio: 32.6% returns, 8% yield, and strategies to optimize income amid market shifts.",
      "url": "https://finnhub.io/api/news?id=62143e9809113f40aaa2c2b687060be2bbc505ad8cfd357aa8c46711ad5182f0"
    }
  }
]